1.0
Apr 13, 2026
Recommend
CEO approval
Business Outlook
Pros
Many dedicated staff Product potential is high
Cons
Negative, divisive culture since the new CEO came on board late 2025. Small company that created a big pharma bureaucratic structure where information feeds to and from leadership are managed by staff who have their own agenda that are not entirely driven by the needs of the patients. Too many chiefs and not nearly enough worker bees. Chaotic and disorganized